Healthy
Conditions
Keywords
Sulpiride, Therapeutic drug monitoring, Pharmacokinetics
Brief summary
The present study was adopted to evaluate the pharmacokinetics of sulpiride after oral administration.
Detailed description
The present study was adopted to evaluate the pharmacokinetics of sulpiride after administration of single oral doses of 50 mg in an open-label, one-way study.
Interventions
DRUGSulpiride
Sponsors
Damanhour University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* At least 18 years old and not more than 45 healthy male volunteers * Actual weight no more than ± 30% from ideal body weight based on sex, height, and body frame * Who had passed all the screening parameters * Free of any drug exposure known to interfere with the pharmacokinetics or assay of sulpiride for at least 10 days prior to the study * Who had to be able to communicate effectively with study personnel, be literate, and able to give consent.
Exclusion criteria
* A clinically significant abnormal physical exam, medical history, or laboratory studies If they showed a sitting SBP of \>140 or \<100 mmHg, DBP \> 90 or \<60mm Hg, or a pulse rate of \> 95 or \< 50 beats/min at screening A history of serious intolerance, allergy, or sensitivity to fexofenadine The use of any prescription drug within the previous month or use of any over-the-counter medication (with the exception of acetaminophen) within the past 14 days A history of blood dyscrasias A history of alcohol or drug abuse within the past year Donation of blood during the 8 weeks prior to the study or plans to donate blood during or within 8 weeks of completing the study Unable to tolerate vein puncture and multiple blood samplings Any surgical/medical condition that might alter drug absorption, distribution, metabolism, or excretion Cannot follow instructions, in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| •Assessment of the bioequivalence of the oral suspension formulation, the oral solution formulation, and the marketed tablet formulation of levofloxacin, on Days 1, 2, and 3, using the marketed tablet as the reference. Pharmacokinetics of sulpiride | The pharmacokinetic analysis is done after blood sampling | Assessment of the pharmacokinetics using compartmental and non compartmental analysis of sulpiride after oral administration |
Countries
Egypt
Outcome results
None listed